查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1324115

性感染疾病(STDs)药物的全球市场

Sexually Transmitted Diseases (STDs) Drug
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

性感染疾病(STDs)药物的全球市场在2030年前将达到1,236亿美元

在COVID-19后改变的商务环境中，2022年估算为600亿美元的性感染疾病(STDs)药物的全球市场在2030年前将达到1,236亿美元，在2022年～2030年间将以年复合成长率9.5％增长。本报告所分析的市场区隔之一的HPV将记录年复合成长率9.8％，到分析期间结束时将达到743亿美元。考虑疫情后的復苏，披衣菌感染领域今后8年的年复合成长率将修正为8.8％。

美国市场估算为162亿美元，中国则将以年复合成长率12.9％增长

美国的性感染疾病(STDs)药物市场在2022年估算为162亿美元。作为世界第2大经济大国的中国，在2022年～2030年的分析期间中将以年复合成长率12.9％推移，2030年之前达到274亿美元的市场规模。其他热门的地区市场有日本和加拿大，在2022年～2030年间将各以7％和7.4％的速度成长。在欧洲市场中，德国预计将以年复合成长率约7.4％成长。

调查对象企业范例

  • AbbVie, Inc.
  • Bayer Healthcare AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Pfizer, Inc.

目录

第1章 调查手法

第2章 摘要整理

  • 市场概要
  • 主要企业
  • 市场趋势与推动因素
  • 全球市场预测

第3章 市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲
  • 亚太地区
  • 澳洲
  • 印度
  • 韩国
  • 其他亚太地区
  • 南美
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他南美国家
  • 中东
  • 伊朗
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯联合大公国
  • 其他中东
  • 非洲

第4章 竞争

简介目录
Product Code: MCP16773

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Sexually Transmitted Diseases (STDs) Drug Market to Reach $123.6 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Sexually Transmitted Diseases (STDs) Drug estimated at US$60 Billion in the year 2022, is projected to reach a revised size of US$123.6 Billion by 2030, growing at aCAGR of 9.5% over the period 2022-2030. HPV, one of the segments analyzed in the report, is projected to record 9.8% CAGR and reach US$74.3 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Chlamydia segment is readjusted to a revised 8.8% CAGR for the next 8-year period.

The U.S. Market is Estimated at $16.2 Billion, While China is Forecast to Grow at 12.9% CAGR

The Sexually Transmitted Diseases (STDs) Drug market in the U.S. is estimated at US$16.2 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$27.4 Billion by the year 2030 trailing a CAGR of 12.9% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7% and 7.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 7.4% CAGR.

Select Competitors (Total 46 Featured) -

  • AbbVie, Inc.
  • Bayer Healthcare AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Pfizer, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Sexually Transmitted Diseases (STDs) Drug - Global Key Competitors Percentage Market Share in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 3: World 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Chlamydia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Chlamydia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 6: World 16-Year Perspective for Chlamydia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Gonorrhea by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Gonorrhea by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 9: World 16-Year Perspective for Gonorrhea by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Syphilis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Syphilis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 12: World 16-Year Perspective for Syphilis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Genital herpes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Genital herpes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 15: World 16-Year Perspective for Genital herpes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for HPV by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 17: World Historic Review for HPV by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 18: World 16-Year Perspective for HPV by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 21: World 16-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 24: World 16-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 27: World 16-Year Perspective for Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 30: World 16-Year Perspective for Other Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 31: World Sexually Transmitted Diseases (STDs) Drug Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for HIV / AIDS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 33: World Historic Review for HIV / AIDS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 34: World 16-Year Perspective for HIV / AIDS by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Antivirals / Antiretrovirals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Antivirals / Antiretrovirals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 37: World 16-Year Perspective for Antivirals / Antiretrovirals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2014, 2023 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2014, 2023 & 2030
  • JAPAN
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2014, 2023 & 2030
  • CHINA
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 58: China 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 61: China 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2014, 2023 & 2030
  • EUROPE
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 64: Europe 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2014, 2023 & 2030
  • FRANCE
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 71: France Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 72: France Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 73: France 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 74: France Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 75: France Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 76: France 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2014, 2023 & 2030
  • GERMANY
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 77: Germany Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 78: Germany Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 79: Germany 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 80: Germany Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 81: Germany Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 82: Germany 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2014, 2023 & 2030
  • ITALY
    • TABLE 83: Italy Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 84: Italy Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 85: Italy 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 86: Italy Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 87: Italy Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 88: Italy 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 89: UK Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 90: UK Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 91: UK 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 92: UK Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 93: UK Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 94: UK 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2014, 2023 & 2030
  • SPAIN
    • TABLE 95: Spain Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 96: Spain Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 97: Spain 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 98: Spain Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 99: Spain Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 100: Spain 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2014, 2023 & 2030
  • RUSSIA
    • TABLE 101: Russia Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 102: Russia Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 103: Russia 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 104: Russia Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 105: Russia Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 106: Russia 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2014, 2023 & 2030
  • REST OF EUROPE
    • TABLE 107: Rest of Europe Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 108: Rest of Europe Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 109: Rest of Europe 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 111: Rest of Europe Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 112: Rest of Europe 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 115: Asia-Pacific 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 118: Asia-Pacific 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 119: Asia-Pacific Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 120: Asia-Pacific Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 121: Asia-Pacific 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2014, 2023 & 2030
  • AUSTRALIA
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
    • TABLE 122: Australia Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 123: Australia Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 124: Australia 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 125: Australia Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 126: Australia Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 127: Australia 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2014, 2023 & 2030
  • INDIA
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
    • TABLE 128: India Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 129: India Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 130: India 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 131: India Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 132: India Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 133: India 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2014, 2023 & 2030
  • SOUTH KOREA
    • TABLE 134: South Korea Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 135: South Korea Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 136: South Korea 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 137: South Korea Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 138: South Korea Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 139: South Korea 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2014, 2023 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 140: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 141: Rest of Asia-Pacific Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 142: Rest of Asia-Pacific 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 143: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 144: Rest of Asia-Pacific Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 145: Rest of Asia-Pacific 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2014, 2023 & 2030
  • LATIN AMERICA
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 148: Latin America 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2023 & 2030
    • TABLE 149: Latin America Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 150: Latin America Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 151: Latin America 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 152: Latin America Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 153: Latin America Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 154: Latin America 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2014, 2023 & 2030
  • ARGENTINA
    • TABLE 155: Argentina Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 156: Argentina Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 157: Argentina 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 158: Argentina Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 159: Argentina Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 160: Argentina 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2014, 2023 & 2030
  • BRAZIL
    • TABLE 161: Brazil Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 162: Brazil Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 163: Brazil 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 164: Brazil Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 165: Brazil Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 166: Brazil 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2014, 2023 & 2030
  • MEXICO
    • TABLE 167: Mexico Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 168: Mexico Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 169: Mexico 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 170: Mexico Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 171: Mexico Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 172: Mexico 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2014, 2023 & 2030
  • REST OF LATIN AMERICA
    • TABLE 173: Rest of Latin America Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 174: Rest of Latin America Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 175: Rest of Latin America 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 176: Rest of Latin America Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 177: Rest of Latin America Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 178: Rest of Latin America 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2014, 2023 & 2030
  • MIDDLE EAST
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 181: Middle East 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2023 & 2030
    • TABLE 182: Middle East Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 183: Middle East Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 184: Middle East 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 185: Middle East Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 186: Middle East Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 187: Middle East 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2014, 2023 & 2030
  • IRAN
    • TABLE 188: Iran Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 189: Iran Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 190: Iran 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 191: Iran Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 192: Iran Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 193: Iran 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2014, 2023 & 2030
  • ISRAEL
    • TABLE 194: Israel Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 195: Israel Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 196: Israel 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 197: Israel Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 198: Israel Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 199: Israel 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2014, 2023 & 2030
  • SAUDI ARABIA
    • TABLE 200: Saudi Arabia Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 201: Saudi Arabia Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 202: Saudi Arabia 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 203: Saudi Arabia Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 204: Saudi Arabia Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 205: Saudi Arabia 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2014, 2023 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 206: UAE Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 207: UAE Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 208: UAE 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 209: UAE Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 210: UAE Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 211: UAE 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2014, 2023 & 2030
  • REST OF MIDDLE EAST
    • TABLE 212: Rest of Middle East Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 213: Rest of Middle East Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 214: Rest of Middle East 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 215: Rest of Middle East Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 216: Rest of Middle East Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 217: Rest of Middle East 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2014, 2023 & 2030
  • AFRICA
    • Sexually Transmitted Diseases (STDs) Drug Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
    • TABLE 218: Africa Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 219: Africa Historic Review for Sexually Transmitted Diseases (STDs) Drug by Disease Type - HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 220: Africa 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Disease Type - Percentage Breakdown of Value Sales for HPV, Chlamydia, HIV / AIDS, Gonorrhea, Genital herpes, Syphilis and Other Disease Types for the Years 2014, 2023 & 2030
    • TABLE 221: Africa Recent Past, Current & Future Analysis for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 222: Africa Historic Review for Sexually Transmitted Diseases (STDs) Drug by Therapy - Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 223: Africa 16-Year Perspective for Sexually Transmitted Diseases (STDs) Drug by Therapy - Percentage Breakdown of Value Sales for Antibiotics, Antivirals / Antiretrovirals, Vaccines and Other Therapies for the Years 2014, 2023 & 2030

IV. COMPETITION